Last reviewed · How we verify
mantadix
At a glance
| Generic name | mantadix |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mantadix CI brief — competitive landscape report
- mantadix updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI